Advertisement
The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
Read Now: Expert Opinions on HIV Cure Research
  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

Medical News

Roche, Trimeris Announce Study Results Indicating Fuzeon, MK-0518 Combination Therapy Effective in Lowering HIV to Undetectable Levels

October 10, 2006

Roche and biopharmaceutical company Trimeris on Thursday announced that their antiretroviral drug Fuzeon -- known generically as enfuvirtide -- in combination with Merck's experimental drug MK-0518 in a recent study decreased HIV viral loads to undetectable levels in up to 95% of study participants, compared with up to 70% in participants who received only MK-0518, the AP/Forbes reports (AP/Forbes, 10/5). The results are from a 24-week, Phase II study of MK-0518 sponsored by Merck, Reuters reports. Fuzeon is in a class of drugs called fusion inhibitors and is designed for HIV/AIDS patients who have failed to respond to other medications. "[R]esponse rates" for the combination Fuzeon-MK-0518 treatment "have never been achieved in clinical trials of HIV patients living with drug-resistant virus," Roche said in a statement (Reuters, 10/5).

Back to other news for October 10, 2006


Reprinted with permission from kaisernetwork.org. You can view the entire Kaiser Daily HIV/AIDS Report, search the archives, or sign up for email delivery at www.kaisernetwork.org/dailyreports/hiv. The Kaiser Daily HIV/AIDS Report is published for kaisernetwork.org, a free service of the Kaiser Family Foundation, by The Advisory Board Company. © 2006 by The Advisory Board Company and Kaiser Family Foundation. All rights reserved.



  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

This article was provided by Henry J. Kaiser Family Foundation. It is a part of the publication Kaiser Daily HIV/AIDS Report. Visit the Kaiser Family Foundation's website to find out more about their activities, publications and services.
 
See Also
More HIV News

Tools
 

Advertisement